Literature DB >> 17152269

Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions.

Stine Sivertsen1, Aasmund Berner, Claire W Michael, Carlos Bedrossian, Ben Davidson.   

Abstract

OBJECTIVE: To analyze potential differences in cadherin expression between ovarian carcinoma/primary peritoneal carcinoma (OC/PPC) and malignant mesothelioma (MM) at this anatomic site. STUDY
DESIGN: MM (N=24) and OC/PPC (N= 53) effusions were analyzed for E-cadherin, N-cadherin and P-cadherin protein expression using immunocytochemistry.
RESULTS: Both MM and OC/PPC cells showed frequent expression of all 3 cadherins. OC/PPC specimens expressed E-cadherin and N-cadherin in 52 of 53 cases and P-cadherin in 51 of 53 cases. MM effusions expressed E-cadherin, N-cadherin and P-cadherin in 22 of 24, 21 of24 and 23 of24 cases, respectively. The differences in the percentage of cadherin-positive cells was weakly significant for P-cadherin (higher expression in MM, p = 0.04), but E-cadherin and N-cadherin expression was comparable (p > 0.05).
CONCLUSION: MM and OC/PPC coexpress different cadherin family members. P-cadherin, E-cadherin and N-cadherin are not useful for differentiation between OC/PPC and MM in effusions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17152269     DOI: 10.1159/000326027

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  11 in total

1.  Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions.

Authors:  Sivan Elloul; Olga Vaksman; Helene Tuft Stavnes; Claes G Trope; Ben Davidson; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2010-03-07       Impact factor: 5.150

2.  E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer.

Authors:  Kristine Ansenberger; Yan Zhuge; Jo Ann J Lagman; Cassandra Richards; Animesh Barua; Janice M Bahr; Dale Buchanan Hales
Journal:  Gynecol Oncol       Date:  2009-03-24       Impact factor: 5.482

3.  Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins.

Authors:  L Carduner; J Leroy-Dudal; C R Picot; O Gallet; F Carreiras; S Kellouche
Journal:  Clin Exp Metastasis       Date:  2014-06-20       Impact factor: 5.150

Review 4.  Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression.

Authors:  Laurie G Hudson; Reema Zeineldin; M Sharon Stack
Journal:  Clin Exp Metastasis       Date:  2008-04-09       Impact factor: 5.150

5.  Epithelial-mesenchymal transition in ovarian carcinoma.

Authors:  Ben Davidson; Claes G Tropé; Reuven Reich
Journal:  Front Oncol       Date:  2012-04-10       Impact factor: 6.244

6.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

7.  HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.

Authors:  Song Yi Ko; Honami Naora
Journal:  Mol Cancer       Date:  2014-07-14       Impact factor: 27.401

8.  SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance.

Authors:  J N Sheets; M Iwanicki; J F Liu; B E Howitt; M S Hirsch; J A A Gubbels; R Drapkin; K A Egland
Journal:  Oncogenesis       Date:  2016-10-24       Impact factor: 7.485

Review 9.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

10.  Heterogeneous Cadherin Expression and Multicellular Aggregate Dynamics in Ovarian Cancer Dissemination.

Authors:  Yuliya Klymenko; Jeffrey Johnson; Brandi Bos; Rachel Lombard; Leigh Campbell; Elizabeth Loughran; M Sharon Stack
Journal:  Neoplasia       Date:  2017-06-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.